Stock BTAI BIOXCEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Real-time Estimate Cboe BZX
Other stock markets
 10:48:54 2024-05-14 EDT 		5-day change 1st Jan Change
2.255 USD +3.20% Intraday chart for BioXcel Therapeutics, Inc. -4.68% -24.06%
05-09 BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-09 Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
AQ
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
AQ
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
AQ
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
AQ
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
AQ
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
AQ
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
AQ
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
AQ
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
AQ
BioXcel Therapeutics Announces Termination of Proposed Public Offering
AQ
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
AQ
BioXcel Therapeutics Announces Proposed Public Offering
AQ
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
AQ
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
AQ
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
AQ
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
AQ
Moore Kuehn, PLLC Encourages BioXcel Therapeutics, Inc. Investors to Contact Law Firm
PR
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
AQ
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
AQ
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BTAI Stock
  4. News BioXcel Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW